Figure 1
![Figure 1. PFS and overall survival. Kaplan-Meier plots of progression-free survival (PFS; A) and overall survival (B) of older early-stage favorable HL patients treated with 2 cycles of AVD (HD13 trial; median observation time [MOT], 57 months), 2 cycles of ABVD (HD10 trial, MOT 84 months; HD13 trial, MOT 58 months) or 4 cycles of ABVD (HD10 trial, MOT 84 months). Pts, patients.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/127/18/10.1182_blood-2015-11-681064/4/2189f1.jpeg?Expires=1735561874&Signature=BPLitTQyTZqXjylpkvwq~34eLSXWeFiMsqnlPR447KB27m1tQYZITQUDx7K90NXnYg736vxIRXME1cWMM75ZUmhCgDMyLliX1D55hrnhjZrOfYpFbN-sqOf10DrE3onp0SWjoWfmFdI5I~kD0CeW7IReu37K6VDsdBtLiBB84fulOfcJ1cnUdsLGrOeygCl2EjXMHB7lMuqsYCqIwpLrgI2xg7tYQQ8XoUDLVCJ1nOFw8TrQizvqEe0x3I62jbHcJ4QjVNuOGAFWqL04Tpo5DXSa4EymGoFcEdw9unOJAZzfD~L0-sxEvyiLYgEiTrgc~crw7NXPjRhMRbsCF9NftA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
PFS and overall survival. Kaplan-Meier plots of progression-free survival (PFS; A) and overall survival (B) of older early-stage favorable HL patients treated with 2 cycles of AVD (HD13 trial; median observation time [MOT], 57 months), 2 cycles of ABVD (HD10 trial, MOT 84 months; HD13 trial, MOT 58 months) or 4 cycles of ABVD (HD10 trial, MOT 84 months). Pts, patients.
